Participant flow

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer · Source last updated 2026-09-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received TAK-186, Dose A as an intravenous (IV) infusion, every week (QW) until disease progression (PD), completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose A is the lowest dose.

   id

   FG000

   title

   Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone

2. description

   Participants received TAK-186, Dose B as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose B is higher than Dose A.

   id

   FG001

   title

   Dose Escalation Phase: TAK-186 - Dose B + Dexamethasone

3. description

   Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose C is higher than Dose B.

   id

   FG002

   title

   Dose Escalation Phase: TAK-186 - Dose B → Dose C + Dexamethasone

4. description

   Participants received TAK-186, Dose B on Day 1 followed by Dose D on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B.

   id

   FG003

   title

   Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone

5. description

   Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose E is higher than Dose C and B.

   id

   FG004

   title

   Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone

6. description

   Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.

   id

   FG005

   title

   Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Double Dexamethasone

7. description

   Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose F on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose F is highest dose and is higher than Dose B and C.

   id

   FG006

   title

   Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose F + Dexamethasone

8. description

   Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B and C.

   id

   FG007

   title

   Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone

9. description

   Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose D is higher than Dose B and C.

   id

   FG008

   title

   Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Double Dexamethasone

10. description

    Participants with non-small cell lung cancer (NSCLC) received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.

    id

    FG009

    title

    Cohort Expansion Phase: NSCLC

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         1

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         0

      10. group Id

          FG009

          num Subjects

          0

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         1

      4. group Id

         FG003

         num Subjects

         1

      5. group Id

         FG004

         num Subjects

         3

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         1

      10. group Id

          FG009

          num Subjects

          7

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         3

      6. group Id

         FG005

         num Subjects

         8

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         0

      9. group Id

         FG008

         num Subjects

         1

      10. group Id

          FG009

          num Subjects

          12

      type

      Sponsor Request

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         6

      5. group Id

         FG004

         num Subjects

         10

      6. group Id

         FG005

         num Subjects

         5

      7. group Id

         FG006

         num Subjects

         2

      8. group Id

         FG007

         num Subjects

         3

      9. group Id

         FG008

         num Subjects

         5

      10. group Id

          FG009

          num Subjects

          12

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         10

      5. group Id

         FG004

         num Subjects

         17

      6. group Id

         FG005

         num Subjects

         13

      7. group Id

         FG006

         num Subjects

         5

      8. group Id

         FG007

         num Subjects

         4

      9. group Id

         FG008

         num Subjects

         8

      10. group Id

          FG009

          num Subjects

          31

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         9

      5. group Id

         FG004

         num Subjects

         16

      6. group Id

         FG005

         num Subjects

         13

      7. group Id

         FG006

         num Subjects

         4

      8. group Id

         FG007

         num Subjects

         3

      9. group Id

         FG008

         num Subjects

         8

      10. group Id

          FG009

          num Subjects

          29

      comment

      Participants who received at least 1 dose of TAK-186 and had a baseline immunogenicity sample and at least 1 postbaseline immunogenicity sample for assessment were included in the population.

      type

      Immunogenicity Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         8

      5. group Id

         FG004

         num Subjects

         14

      6. group Id

         FG005

         num Subjects

         11

      7. group Id

         FG006

         num Subjects

         4

      8. group Id

         FG007

         num Subjects

         2

      9. group Id

         FG008

         num Subjects

         7

      10. group Id

          FG009

          num Subjects

          0

      comment

      Participants who received at least 3 target doses of TAK-186 in a dose cohort, or at least 2 target doses of TAK-186, or experienced a DLT within the DLT-evaluation period were included in DLT evaluable population.

      type

      Dose Limiting Toxicity (DLT) Evaluable Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         2

      5. group Id

         FG004

         num Subjects

         1

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         1

      9. group Id

         FG008

         num Subjects

         1

      10. group Id

          FG009

          num Subjects

          0

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         8

      5. group Id

         FG004

         num Subjects

         16

      6. group Id

         FG005

         num Subjects

         13

      7. group Id

         FG006

         num Subjects

         4

      8. group Id

         FG007

         num Subjects

         3

      9. group Id

         FG008

         num Subjects

         7

      10. group Id

          FG009

          num Subjects

          31

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The study comprised two phases: a Dose-Escalation Phase and a Cohort Expansion Phase. The dose-escalation phase was followed by a cohort-expansion phase. The study was terminated early due to the sponsor's strategic decision to discontinue the TAK-186 development program based on the limited anti-cancer activity of TAK-186 as a single agent.

recruitment Details

A total of 95 participants took part in the study from 08 March 2021 to 17 June 2025.

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice